Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)

Yeni, P ; LaMarca, A ; Berger, D ; Cimoch, P ; Lazzarin, A ; Salvato, P ; Smaill, FM ; Teofilo, E ; Madison, SJ ; Nichols, WG ; Adkison, KK ; Bonny, T ; Millard, J ; McCarty, D

HIV medicine, 2009-02, Vol.10 (2), p.116-124 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível